The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
P-Glycoprotein Antibody Functionalized Carbon Nanotube Overcomes the Multidrug Resistance of Human Leukemia Cells
Abstract
Multidrug resistance (MDR), which is related to cancer chemotherapy, tumor stem cells, and tumor metastasis, is a huge obstacle for the effective cancer therapy. One of the underlying mechanisms of MDR is the increased efflux of anticancer drugs by overexpressed P-glycoprotein (P-gp) of multidrug resistant cells. In this work, the antibody of P-gp (anti-P-gp) functionalized water-soluble single-walled carbon nanotubes (Ap-SWNTs) loaded with doxorubicin (Dox), Dox/Ap-SWNTs, were synthesized for challenging the MDR of K562 human leukemia cells. The resulting Ap-SWNTs could not only specifically recognize the multidrug resistant human leukemia cells (K562R), but also demonstrate the effective loading and controllable release performance for Dox toward the target K562R cells by exposing to near-infrared radiation (NIR). The recognition capability of Ap-SWNTs toward the K562R cells was confirmed by flow cytometry (FCM) and confocal laser scanning microscopy (CLSM). The binding affinity of Ap-SWNTs toward drug-resistant K562R cells was ca. 23-fold higher than that toward drug-sensitive K562S cells. Additionally, CLSM indicated that Ap-SWNTs could specifically localize on the cell membrane of K562R cells and the fluorescence of Dox in K562R cells could be significantly enhanced after the employment of Ap-SWNTs as carrier. Moreover, the composite of Dox and Ap-SWNTs (Dox/Ap-SWNTs) expressed 2.4-fold higher cytotoxicity and showed the significant cell proliferation suppression toward K562R leukemia cells (p < 0.05) as compared with free Dox which is popularly employed in clinic trials. These results suggest that the Ap-SWNTs are the promising drug delivery vehicle for overcoming the MDR induced by the overexpression of P-gp on cell membrane. Ap-SWNTs loaded with drug molecules could be used to suppress the proliferation of multidrug resistant cells, destroy the tumor stem cells, and inhibit the metastasis of tumor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552
Tumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668
Liposomes in drug delivery: Progress and limitations
Sharma, A. (1997) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(97)00135-x · Cited by 1,253
Oops they did it again! Carbon nanotubes hoax scientists in viability assays
Wörle-Knirsch, J. M., Pulskamp, K., & Krug, H. F. (2006) · Nano Letters · doi:10.1021/nl060177c · Cited by 994
Cited by
Controlled drug delivery vehicles for cancer treatment and their performance
Senapati, S., Mahanta, A. K., Kumar, S., & Maiti, P. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-017-0004-3 · Cited by 2,167
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Chitosan‐Functionalized Graphene Oxide as a Nanocarrier for Drug and Gene Delivery
Bao, H., Pan, Y., Ping, Y., Sahoo, N. G., Wu, T., Li, L., Li, J., & Gan, L. H. (2011) · Small · doi:10.1002/smll.201100191 · Cited by 895
Wang, F., Wang, Y.-C., Dou, S., Xiong, M.-H., Sun, T.-M., & Wang, J. (2011) · ACS Nano · doi:10.1021/nn200007z · Cited by 813
Carbon nanotubes for delivery of small molecule drugs
Wong, B. S., Yoong, S. L., Jagusiak, A., Panczyk, T., Ho, H. K., Ang, W. H., & Pastorin, G. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.005 · Cited by 585
Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy
Parhi, P., Mohanty, C., & Sahoo, S. K. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.05.010 · Cited by 573
Kievit, F. M., & Zhang, M. (2011) · Advanced Materials · doi:10.1002/adma.201102313 · Cited by 496
Gao, Y., Chen, Y., Ji, X., He, X., Yin, Q., Zhang, Z., Shi, J., & Li, Y. (2011) · ACS Nano · doi:10.1021/nn2033105 · Cited by 400
Carbon nanotubes: a novel material for multifaceted applications in human healthcare
Kumar, S., Rani, R., Dilbaghi, N., Tankeshwar, K., & Kim, K.-H. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00517a · Cited by 397
A new era of cancer treatment: carbon nanotubes as drug delivery tools
Seifalian, A. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s16923 · Cited by 366
Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor
Yin, Q., Shen, J., Zhang, Z., Yu, H., & Li, Y. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.04.011 · Cited by 365
Carbon Nanotubes in Cancer Therapy and Drug Delivery
Elhissi, A. M. A., Ahmed, W., Hassan, I. U., Dhanak, V. R., & D'Emanuele, A. (2012) · Journal of Drug Delivery · doi:10.1155/2012/837327 · Cited by 332
Nanotechnology applied to overcome tumor drug resistance
Gao, Z., Zhang, L., & Sun, Y. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.051 · Cited by 303
Li, R., Guiney, L. M., Chang, C. H., Mansukhani, N. D., Ji, Z., Wang, X., Liao, Y.-P., Jiang, W., Sun, B., Hersam, M. C., et al. (2018) · ACS Nano · doi:10.1021/acsnano.7b07737 · Cited by 278
Self-citationClinical therapies and nano drug delivery systems for urinary bladder cancer
Jain, P., Kathuria, H., & Momin, M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107871 · Cited by 89
Metadata
- Authors
- Li, R., Wu, R., Zhao, L., Wu, M., Yang, L., & Zou, H.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2010-02-11
- Volume
- 4
- Issue
- 3
- Pages
- 1399-1408
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W2113604872
- Cited by
- 245
- References
- 4
- FWCI
- 9.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.